CERS vs SHC
CERS: Cerus is a developer of blood safety technologies, specifically pathogen reduction systems designed to protect the blood supply from transfusion-transmitted infections. SHC: A global sterilization and lab testing partner ensuring the safety of medical devices and pharmaceuticals for 40+ top-50 device makers and 9 of top-10 pharma companies.
Side-by-side fundamentals
| Metric | CERS | SHC | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $2.15 | $17.86 | |
| Market cap as of 2026-08-03 | $433M | $5.1B | |
| P/E as of 2026-08-03 | n/a | 43.53 | |
| PEG as of 2026-08-03 | n/a | 4.31 | |
| Net margin as of 2026-08-03 | -3.9% | +9.9% | SHC higher |
| Gross margin as of 2026-08-03 | +58.4% | +55.3% | CERS higher |
| Operating margin as of 2026-08-03 | -1.3% | +29.0% | SHC higher |
| ROE as of 2026-08-03 | -15.4% | +20.6% | SHC higher |
| ROA as of 2026-08-03 | -4.4% | +3.6% | SHC higher |
| Debt / equity as of 2026-08-03 | 1.26 | 3.59 | CERS lower |
| Revenue growth (YoY) as of 2026-08-03 | +18.4% | +7.4% | CERS higher |
| Revenue CAGR (3y) SEC XBRL | +7.5% | +5.1% | CERS higher |
| Beta as of 2026-08-03 | 1.66 | 1.10 | |
| 1-year return as of 2026-07-31 close | +68.0% | +55.4% | CERS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.